Open AccessFenofibrate Reduces Systemic Inflammation Markers Independent of Its Effects on Lipid and Glucose Metabolism in Patients with the Metabolic Syndrome
Author(s) -
Renata Belfort,
Rachele Berria,
John E. Cornell,
Kenneth Cusi
Publication year - 2010
Publication title -
the journal of clinical endocrinology and metabolism/journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2009-1487
Subject(s) - medicine , endocrinology , insulin resistance , adiponectin , fenofibrate , metabolic syndrome , adipokine , adipose tissue , insulin , glucose clamp technique , triglyceride , carbohydrate metabolism , leptin , diabetes mellitus , cholesterol , pancreatic hormone , obesity
Fenofibrate is a peroxisome proliferator-activated receptor alpha agonist widely used in clinical practice, but its mechanism of action is incompletely understood.